1
|
Carrasquilla M, Paudel N, Collins BT, Anderson E, Krochmal R, Margolis M, Balawi A, DeBlois D, Giaccone G, Kim C, Liu S, Lischalk JW. High-Risk Non-Small Cell Lung Cancer Treated With Active Scanning Proton Beam Radiation Therapy and Immunotherapy. Adv Radiat Oncol 2022; 8:101125. [PMID: 36578277 PMCID: PMC9791120 DOI: 10.1016/j.adro.2022.101125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2022] [Accepted: 10/31/2022] [Indexed: 11/27/2022] Open
Abstract
Purpose Non-small cell lung cancer (NSCLC) is a deadly malignancy that is frequently diagnosed in patients with significant medical comorbidities. When delivering local and regional therapy, an exceedingly narrow therapeutic window is encountered, which often precludes patients from receiving aggressive curative therapy. Radiation therapy advances including particle therapy have been employed in an effort to expand this therapeutic window. Here we report outcomes with the use of proton therapy with curative intent and immunotherapy to treat patients diagnosed with high-risk NSCLC. Methods and Materials Patients were determined to be high risk if they had severe underlying cardiopulmonary dysfunction, history of prior thoracic radiation therapy, and/or large volume or unfavorable location of disease (eg, bilateral hilar involvement, supraclavicular involvement). As such, patients were determined to be ineligible for conventional x-ray-based radiation therapy and were treated with pencil beam scanning proton beam therapy (PBS-PBT). Patients who demonstrated excess respiratory motion (ie, greater than 1 cm in any dimension noted on the 4-dimensional computed tomography simulation scan) were deemed to be ineligible for PBT. Toxicity was reported using the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Overall survival and progression-free survival were calculated using the Kaplan-Meier method. Results A total of 29 patients with high-risk NSCLC diagnoses were treated with PBS-PBT. The majority (55%) of patients were defined as high risk due to severe cardiopulmonary dysfunction. Most commonly, patients were treated definitively to a total dose of 6000 cGy (relative biological effectiveness) in 30 fractions with concurrent chemotherapy. Overall, there were a total of 6 acute grade 3 toxicities observed in our cohort. Acute high-grade toxicities included esophagitis (n = 4, 14%), dyspnea (n = 1, 3.5%), and cough (n = 1, 3.5%). No patients developed grade 4 or higher toxicity. The majority of patients went on to receive immunotherapy, and high-grade pneumonitis was rare. Two-year progression-free and overall survival was estimated to be 51% and 67%, respectively. COVID-19 was confirmed or suspected to be responsible for 2 patient deaths during the follow-up period. Conclusions Radical PBS-PBT treatment delivered in a cohort of patients with high-risk lung cancer with immunotherapy is feasible with careful multidisciplinary evaluation and rigorous follow-up.
Collapse
Affiliation(s)
- Michael Carrasquilla
- Department of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC
| | - Nitika Paudel
- Department of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC
| | - Brian T. Collins
- Department of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC
| | - Eric Anderson
- Division of Pulmonary and Critical Care Medicine, MedStar Georgetown University Hospital, Washington, DC
| | - Rebecca Krochmal
- Division of Pulmonary and Critical Care Medicine, MedStar Georgetown University Hospital, Washington, DC
| | - Marc Margolis
- Division of Thoracic Surgery, MedStar Georgetown University Hospital, Washington, DC
| | - Ahssan Balawi
- Department of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC
| | - David DeBlois
- Department of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC
| | - Giuseppe Giaccone
- Department of Hematology and Oncology, Weill Cornell Medical Center, New York, New York
| | - Chul Kim
- Lombardi Cancer Center, MedStar Georgetown University Hospital, Washington, DC
| | - Stephen Liu
- Lombardi Cancer Center, MedStar Georgetown University Hospital, Washington, DC
| | - Jonathan W. Lischalk
- Department of Radiation Oncology, Perlmutter Cancer Center at New York University Langone Hospital – Long Island, New York, New York,Corresponding author: Jonathan W. Lischalk, MD
| |
Collapse
|
2
|
Piras A, Venuti V, D’Aviero A, Cusumano D, Pergolizzi S, Daidone A, Boldrini L. Covid-19 and radiotherapy: a systematic review after 2 years of pandemic. Clin Transl Imaging 2022; 10:611-630. [PMID: 35910079 PMCID: PMC9308500 DOI: 10.1007/s40336-022-00513-9] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2022] [Accepted: 07/12/2022] [Indexed: 02/08/2023]
Abstract
Introduction Following the Covid-19 pandemic spread, changes in clinical practice were necessary to limit the pandemic diffusion. Also, oncological practice has undergone changes with radiotherapy (RT) treatments playing a key role.Although several experiences have been published, the aim of this review is to summarize the current evidence after 2 years of pandemic to provide useful conclusions for clinicians. Methods A Pubmed/MEDLINE and Embase systematic review was conducted. The search strategy was "Covid AND Radiotherapy" and only original articles in the English language were considered. Results A total of 2.733 papers were obtained using the mentioned search strategy. After the complete selection process, a total of 281 papers were considered eligible for the analysis of the results. Discussion RT has played a key role in Covid-19 pandemic as it has proved more resilient than surgery and chemotherapy. The impact of the accelerated use of hypofractionated RT and telemedicine will make these strategies central also in the post-pandemic period.
Collapse
Affiliation(s)
- Antonio Piras
- Radioterapia Oncologica, Villa Santa Teresa, Palermo, Italy
| | - Valeria Venuti
- Radioterapia Oncologica, Università degli Studi di Palermo, Palermo, Italy
| | - Andrea D’Aviero
- Radiation Oncology, Mater Olbia Hospital, Olbia, Sassari Italy
| | | | - Stefano Pergolizzi
- Radiation Oncology Unit, Department of Biomedical, Dental Science and Morphological and Functional Images, University of Messina, Messina, Italy
| | | | - Luca Boldrini
- Dipartimento di Diagnostica per immagini, Radioterapia Oncologica ed Ematologia, UOC Radioterapia Oncologica - Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy
- Università Cattolica del Sacro Cuore, Roma, Italy
| |
Collapse
|
3
|
Yurut Caloglu V, Akmansu M, Yalman D, Karabulut Gul S, Kocak Z, Arican Alicikus Z, Serarslan A, Akyurek S, Zoto Mustafayev T, Demiroz C, Colpan Oksuz D, Kanyilmaz G, Altinok P, Kaytan Saglam E, Yentek Balkanay A, Akboru H, Keven E, Yildirim B, Onal C, Igdem S, Ozkan E, Ozdener F, Caloglu M. Evaluation of Nutritional Status and Anxiety Levels in Patients Applying to the Radiation Oncology Outpatient Clinic during the COVID-19 Pandemic: Turkish Society for Radiation Oncology Group Study (TROD 12:02). Nutr Cancer 2022; 74:3601-3610. [DOI: 10.1080/01635581.2022.2093386] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Affiliation(s)
| | - Muge Akmansu
- Department of Radiation Oncology, Gazi University, Ankara, Turkey
| | - Deniz Yalman
- Department of Radiation Oncology, Ege University, Izmir, Turkey
| | - Sule Karabulut Gul
- Department of Radiation Oncology, Dr. Lutfi Kirdar Kartal Research and Training Hospital, Istanbul, Turkey
| | - Zafer Kocak
- Department of Radiation Oncology, Trakya University, Edirne, Turkey
| | | | | | - Serap Akyurek
- Department of Radiation Oncology, Ankara University, Ankara, Turkey
| | | | - Candan Demiroz
- Department of Radiation Oncology, Uludag University, Bursa, Turkey
| | - Didem Colpan Oksuz
- Department of Radiation Oncology, Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey
| | - Gul Kanyilmaz
- Department of Radiation Oncology, Necmettin Erbakan University, Konya, Istanbul
| | - Pelin Altinok
- Department of Radiation Oncology, University of Health Sciences Umraniye Research and Training Hospital, Istanbul, Turkey
| | - Esra Kaytan Saglam
- Department of Radiation Oncology, Istanbul University Medical Faculty, Istanbul, Turkey
| | - Ayben Yentek Balkanay
- Department of Radiation Oncology, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey
| | - Halil Akboru
- Department of Radiation Oncology, University of Health Sciences, Okmeydani Hospital, Istanbul, Turkey
| | - Emine Keven
- Department of Radiation Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, Ankara, Turkey
| | - Berna Yildirim
- Department of Radiation Oncology, Adana Baskent University, Adana, Istanbul
| | - Cem Onal
- Department of Radiation Oncology, Adana Baskent University, Adana, Istanbul
| | - Sefik Igdem
- Department of Radiation Oncology, Istanbul Bilgi University, Istanbul, Turkey
| | - Emre Ozkan
- Medical Department, Nutricia, Advanced Medical Nutrition, Istanbul, Turkey
| | - Fatih Ozdener
- School of Medicine, Department of Pharmacology, Bahcesehir University, İstanbul, Turkey
| | - Murat Caloglu
- Department of Radiation Oncology, Trakya University, Edirne, Turkey
| |
Collapse
|
4
|
Walker MJ, Wang J, Mazuryk J, Skinner SM, Meggetto O, Ashu E, Habbous S, Nazeri Rad N, Espino-Hernández G, Wood R, Chaudhry M, Vahid S, Gao J, Gallo-Hershberg D, Gutierrez E, Zanchetta C, Langer D, Zwicker V, Rey M, Tammemägi MC, Tinmouth J, Kupets R, Chiarelli AM, Singh S, Warde P, Forbes L, Dobranowski J, Irish J, Rabeneck L. Delivery of Cancer Care in Ontario, Canada, During the First Year of the COVID-19 Pandemic. JAMA Netw Open 2022; 5:e228855. [PMID: 35467731 PMCID: PMC9039771 DOI: 10.1001/jamanetworkopen.2022.8855] [Citation(s) in RCA: 33] [Impact Index Per Article: 16.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
IMPORTANCE The COVID-19 pandemic has impacted cancer systems worldwide. Quantifying the changes is critical to informing the delivery of care while the pandemic continues, as well as for system recovery and future pandemic planning. OBJECTIVE To quantify change in the delivery of cancer services across the continuum of care during the COVID-19 pandemic. DESIGN, SETTING, AND PARTICIPANTS This population-based cohort study assessed cancer screening, imaging, diagnostic, treatment, and psychosocial oncological care services delivered in pediatric and adult populations in Ontario, Canada (population 14.7 million), from April 1, 2019, to March 1, 2021. Data were analyzed from May 1 to July 31, 2021. EXPOSURES COVID-19 pandemic. MAIN OUTCOMES AND MEASURES Cancer service volumes from the first year of the COVID-19 pandemic, defined as April 1, 2020, to March 31, 2021, were compared with volumes during a prepandemic period of April 1, 2019, to March 31, 2020. RESULTS During the first year of the pandemic, there were a total of 4 476 693 cancer care services, compared with 5 644 105 services in the year prior, a difference of 20.7% fewer services of cancer care, representing a potential backlog of 1 167 412 cancer services. While there were less pronounced changes in systemic treatments, emergency and urgent imaging examinations (eg, 1.9% more parenteral systemic treatments) and surgical procedures (eg, 65% more urgent surgical procedures), major reductions were observed for most services beginning in March 2020. Compared with the year prior, during the first pandemic year, cancer screenings were reduced by 42.4% (-1 016 181 screening tests), cancer treatment surgical procedures by 14.1% (-8020 procedures), and radiation treatment visits by 21.0% (-141 629 visits). Biopsies to confirm cancer decreased by up to 41.2% and surgical cancer resections by up to 27.8% during the first pandemic wave. New consultation volumes also decreased, such as for systemic treatment (-8.2%) and radiation treatment (-9.3%). The use of virtual cancer care increased for systemic treatment and radiation treatment and psychosocial oncological care visits, increasing from 0% to 20% of total new or follow-up visits prior to the pandemic up to 78% of total visits in the first pandemic year. CONCLUSIONS AND RELEVANCE In this population-based cohort study in Ontario, Canada, large reductions in cancer service volumes were observed. While most services recovered to prepandemic levels at the end of the first pandemic year, a substantial care deficit likely accrued. The anticipated downstream morbidity and mortality associated with this deficit underscore the urgent need to address the backlog and recover cancer care and warrant further study.
Collapse
Affiliation(s)
- Meghan J. Walker
- Ontario Health–Cancer Care Ontario, Toronto, Canada
- Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
| | | | | | | | | | - Eta Ashu
- Ontario Health–Cancer Care Ontario, Toronto, Canada
| | | | | | | | - Ryan Wood
- Ontario Health–Cancer Care Ontario, Toronto, Canada
| | | | - Saba Vahid
- Ontario Health–Cancer Care Ontario, Toronto, Canada
| | - Julia Gao
- Ontario Health–Cancer Care Ontario, Toronto, Canada
| | - Daniela Gallo-Hershberg
- Ontario Health–Cancer Care Ontario, Toronto, Canada
- Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada
| | | | | | | | | | - Michelle Rey
- Ontario Health–Cancer Care Ontario, Toronto, Canada
| | - Martin C. Tammemägi
- Ontario Health–Cancer Care Ontario, Toronto, Canada
- Department of Health Sciences, Brock University, St Catharines, Canada
| | - Jill Tinmouth
- Ontario Health–Cancer Care Ontario, Toronto, Canada
- Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
- ICES, Toronto, Canada
- Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Canada
- Department of Medicine, University of Toronto, Toronto, Canada
| | - Rachel Kupets
- Ontario Health–Cancer Care Ontario, Toronto, Canada
- Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada
- Department of Obstetrics and Gynecology, University of Toronto, Toronto, Canada
| | - Anna M. Chiarelli
- Ontario Health–Cancer Care Ontario, Toronto, Canada
- Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
| | - Simron Singh
- Ontario Health–Cancer Care Ontario, Toronto, Canada
- Department of Medicine, University of Toronto, Toronto, Canada
- Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada
- Department of Medical Oncology, Sunnybrook Health Sciences Centre, Toronto, , Canada
| | - Padraig Warde
- Ontario Health–Cancer Care Ontario, Toronto, Canada
- Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Canada
- Department of Radiation Oncology, University of Toronto, Toronto, Canada
| | - Leta Forbes
- Ontario Health–Cancer Care Ontario, Toronto, Canada
- Department of Medical Oncology, R.S. McLaughlin Durham Regional Cancer Centre, Oshawa, Canada
| | - Julian Dobranowski
- Ontario Health–Cancer Care Ontario, Toronto, Canada
- Department of Radiology, McMaster University, Hamilton, Canada
- Niagara Health, St Catharines, Ontario, Canada
| | - Jonathan Irish
- Ontario Health–Cancer Care Ontario, Toronto, Canada
- Department of Otolaryngology–Head and Neck Surgery, University of Toronto, Toronto, Canada
- Department of Surgical Oncology, Princess Margaret Cancer Centre, Toronto, Canada
| | - Linda Rabeneck
- Ontario Health–Cancer Care Ontario, Toronto, Canada
- Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
- ICES, Toronto, Canada
- Department of Medicine, University of Toronto, Toronto, Canada
| |
Collapse
|
5
|
Borghetti P, Branz J, Volpi G, Pancera S, Buraschi R, Bianchi LNC, Bonù ML, Greco D, Facheris G, Tomasi C, Pini L, Bezzi M, Grisanti S, Gallazzi MS, Borghesi A, Buglione di Monale E Bastia M. Home-based pulmonary rehabilitation in patients undergoing (chemo)radiation therapy for unresectable lung cancer: a prospective explorative study. LA RADIOLOGIA MEDICA 2022; 127:1322-1332. [PMID: 36217071 PMCID: PMC9551604 DOI: 10.1007/s11547-022-01562-w] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/14/2022] [Accepted: 09/19/2022] [Indexed: 11/06/2022]
Abstract
AIMS The prevention of pulmonary toxicity is an important goal for patient candidate to radiation therapy for lung cancer. There is a lack of evidence on the role of exercise training for patients with unresectable stage III lung cancer candidated to radical treatment. The aim of this study was to evaluate the feasibility of a home-based pulmonary rehabilitation (PR) program and to identify reliable tools in terms of respiratory function, exercise capacity and quality of life. METHODS Patients' recruitment lasted from April 2020 till February 2022. The PR program was proposed concomitantly to radiation therapy to the first 20 patients (interventional group, IG), and the other 20 patients were identified as an observational group (OG). All patients were assessed at baseline (T0) and after 8 weeks (T2) with 6 minute walking test (6MWT), modified Borg Scale (mBORG), SF-36 questionnaire (SF-36) and pulmonary function test (PFT); after 4 weeks (T1), only SF-36 was administered. RESULTS A decrease of 13.8 m in the walked-distance was registered in the OG between T0 and T2 (p = 0.083). Instead, an increase of 56.6 m in the distance walked was recorded in the IG between T0 and T2 (p ≤ 0.001). In the OG, the mBORG scores showed a negative trend. On the contrary, in the IG, these scores showed a slight improvement. In the OG, all the items of SF-36 scores decreased between T0 and T1. In the IG, an increased trend from T0 to T2 was observed for all the items of SF-36. No clinically significant variations were detected from baseline to T2 in both groups regarding PFT. CONCLUSION The 6MWT, mBORG and SF-36 resulted as useful tools to assess the role of a PR program. A significant gain in functional exercise capacity and a prevention of the physiological impairment of QoL during radio(chemo)therapy was registered.
Collapse
Affiliation(s)
- Paolo Borghetti
- Radiation Oncology Department, ASST Spedali Civili and University of Brescia, P.le Spedali Civili, 1, 24123, Brescia, Lombardia, Italy
| | - Jacopo Branz
- IRCSS Fondazione Don Carlo Gnocchi, Milan, Italy
| | - Giulia Volpi
- Radiation Oncology Department, ASST Spedali Civili and University of Brescia, P.le Spedali Civili, 1, 24123, Brescia, Lombardia, Italy.
| | | | | | | | - Marco Lorenzo Bonù
- Radiation Oncology Department, ASST Spedali Civili and University of Brescia, P.le Spedali Civili, 1, 24123, Brescia, Lombardia, Italy
| | - Diana Greco
- Radiation Oncology Department, ASST Spedali Civili and University of Brescia, P.le Spedali Civili, 1, 24123, Brescia, Lombardia, Italy
| | - Giorgio Facheris
- Radiation Oncology Department, ASST Spedali Civili and University of Brescia, P.le Spedali Civili, 1, 24123, Brescia, Lombardia, Italy
| | - Cesare Tomasi
- Radiation Oncology Department, ASST Spedali Civili and University of Brescia, P.le Spedali Civili, 1, 24123, Brescia, Lombardia, Italy
| | - Laura Pini
- Respiratory Medicine Unit, Deparment of Clinical and Experimental Sciences, ASST Spedali Civili, University of Brescia, Brescia, Italy
| | - Michela Bezzi
- Division of Pneumology, University Hospital ASST Spedali Civili of Brescia, Brescia, Italy
| | - Salvatore Grisanti
- Medical Oncology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy
| | - Maria Sole Gallazzi
- Thoracic Surgery Unit, Cardiothoracic Department, Spedali Civili, Brescia, Italy
| | - Andrea Borghesi
- Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia - ASST Spedali Civili of Brescia, Brescia, Italy
| | | |
Collapse
|
6
|
Magrini SM, Guerini AE, Borghetti P, Volpi G, Triggiani L, Costa L, Pegurri L, Spiazzi L, Buglione M. Universal testing for COVID-19 in patients undergoing cancer treatment during the second outbreak in Brescia. TUMORI JOURNAL 2021; 108:278-282. [PMID: 34405756 DOI: 10.1177/03008916211034917] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND The impact of coronavirus disease 2019 (COVID-19) has been overwhelming on patients with cancer, who may be at higher risk of developing severe disease. During the second COVID-19 outbreak in Italy, we planned universal microbiologic screening for patients scheduled for antineoplastic treatment. METHODS All patients with planned active treatment at Brescia University Radiation Oncology Department were screened for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA with repeated nasopharyngeal swabs (NPS) from October 31, 2020. Treatment continuation, suspension, or delay was modulated for patients testing positive according to clinical presentation. RESULTS From October 31, 2020, to February 6, 2021, 636 patients were enrolled and 1243 NPS were performed, of which 28 (2.25%) were positive. The infection rate was 2.52%; 81.3% of the patients with a positive NPS were asymptomatic, 2 had mild disease, and 1 severe disease that led to death. All patients already on treatment with mild or asymptomatic COVID-19 carried on the therapy with no or minimal delay. Median delay for patients with infection detected before treatment start was 16.5 days. CONCLUSIONS Detected incidence of COVID-19 was lower during the second outbreak in our patients (2.52% vs 3.23%), despite the extensive testing schedule, and substantiates the high rate of asymptomatic infections and the low mortality among patients with COVID-19 (6.3% vs 38.5% during the first outbreak). Universal SARS-CoV-2 screening for all patients with planned treatment might allow early identification of patients with COVID-19, resulting in timely management that could improve clinical outcomes and prevent spread of the infection.
Collapse
Affiliation(s)
- Stefano M Magrini
- Department of Radiation Oncology, Università degli Studi di Brescia, Brescia University, Brescia, Italy
| | - Andrea E Guerini
- Department of Radiation Oncology, Università degli Studi di Brescia, Brescia University, Brescia, Italy
| | - Paolo Borghetti
- Department of Radiation Oncology, ASST Spedali Civili di Brescia, Brescia, Italy
| | - Giulia Volpi
- Department of Radiation Oncology, Università degli Studi di Brescia, Brescia University, Brescia, Italy
| | - Luca Triggiani
- Department of Radiation Oncology, Università degli Studi di Brescia, Brescia University, Brescia, Italy
| | - Loredana Costa
- Department of Radiation Oncology, ASST Spedali Civili di Brescia, Brescia, Italy
| | - Ludovica Pegurri
- Department of Radiation Oncology, ASST Spedali Civili di Brescia, Brescia, Italy
| | - Luigi Spiazzi
- Department of Radiation Oncology, ASST Spedali Civili di Brescia, Brescia, Italy
| | - Michela Buglione
- Department of Radiation Oncology, Università degli Studi di Brescia, Brescia University, Brescia, Italy
| |
Collapse
|
7
|
A Systematic Review and Meta-Analysis of Clinical Characteristics and Outcomes in Patients With Lung Cancer with Coronavirus Disease 2019. JTO Clin Res Rep 2021; 2:100141. [PMID: 33437971 PMCID: PMC7790456 DOI: 10.1016/j.jtocrr.2020.100141] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2020] [Accepted: 12/26/2020] [Indexed: 12/15/2022] Open
Abstract
Cancer is considered to be an independent risk factor for severe illness and higher mortality in patients with coronavirus disease 2019 (COVID-19). These adverse outcomes have been suspected to be more severe in patients with lung cancer. The objective of this systematic review and meta-analysis is to outline patient characteristics, challenges in diagnosis and treatment, and outcomes of patients with lung cancer with COVID-19. A comprehensive search was conducted using EMBASE and PubMed databases using the terms “COVID” and “cancer.” Studies that reported clinical characteristics or outcomes of patients with lung cancer with COVID-19 were then systematically identified. Meta-analysis for COVID-19 related mortality associated with lung cancer compared with other cancer types was conducted. The results were reported as OR and confidence intervals using the mixed-effects logistic regression model. The most frequently reported clinical findings in patients with lung cancer with COVID-19 were fever and cough, with 68% and 61%, respectively. Laboratory and radiographic findings were consistent with broadly reported data. The meta-analysis noted a statistically significant increase in mortality rate in patients with lung cancer compared with other patients with cancer, with an OR of 1.62 (95% confidence interval: 1.06–2.48). Patients with lung cancer with COVID-19 also reflected greater severity of illness and higher rates of intensive care unit admissions and mechanical ventilation. COVID-19 in patients with lung cancer is associated with severe disease and increased mortality relative to patients with other malignancies and the general population. There is conflicting evidence on the effect of specific lung cancer treatments on outcomes. Until more definitive data is available, lung cancer–directed treatment should be continued or restarted as early as possible in mild to moderate cases to prevent worsening and cancer-related mortality. Patients with lung cancer and coronavirus disease 2019 infection have higher mortality rates compared with patients with other cancer types. Rates of severe illness, intensive care unit admissions, and mechanical ventilation are also higher in patients with lung cancer. Clinical, laboratory, and radiographic characteristics are similar to reports in the general population. There is conflicting data regarding the effect of specific lung cancer treatments on outcomes.
Collapse
|
8
|
He J, Yang L, Tao Z, Yang J, Zhou Y, Wang R, Zhang Y, Huang Y, Zhou L, Sun B, Gao J. Impact of the 2019 Novel Coronavirus Disease (COVID-19) Epidemic on Radiotherapy-Treated Patients with Cancer: A Single-Center Descriptive Study. Cancer Manag Res 2021; 13:37-43. [PMID: 33442292 PMCID: PMC7800447 DOI: 10.2147/cmar.s281323] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2020] [Accepted: 12/16/2020] [Indexed: 12/23/2022] Open
Abstract
Introduction The present study investigated hospitalization data of patients receiving radiotherapy at Anhui Cancer Hospital during the COVID-19 epidemic and analyzed the impact of the epidemic on the clinical data of radiotherapy patients to provide references for the feasibility and safety of radiotherapy at other medical institutions. Methods The present study performed a retrospective analysis of hospitalization data of patients undergoing radiotherapy at the Radiation Department (from January 5 to March 19, 2020 according to the Chinese lunar calendar), who were defined as the epidemic group. Hospitalization data for patients undergoing radiotherapy during the same period in 2019 were used as the control group for comparison with the epidemic group in terms of sex, age, distribution of various cancer types, hospitalization costs, average length of stay, completion rate of radiotherapy, treatment mode, and purpose of radiotherapy. Results A total of 79 and 115 patients received radiotherapy in the epidemic group and control group, respectively. The number of patients who received radiotherapy declined 31.3% during the epidemic period. The number of head and neck cancer patients who received radiotherapy was 36 (45.57%) in the epidemic group and 32 (27.83%) in the control group, which was a significant difference (χ2=6.476, P=0.011). The proportions of patients with other types of cancer decreased, with no significant difference between the two groups (P>0.05). No significant differences between the two groups were found in terms of other hospitalization data (P>0.05). Conclusion The total number of patients who received radiotherapy decreased during the epidemic period, but the proportion of head and neck cancer increased. The epidemic had no significant effect on other hospitalization data. While strengthening prevention and control measures, we should actively perform radiotherapy to ensure that cancer patients receive timely and safe treatment.
Collapse
Affiliation(s)
- Jian He
- Department of Radiation Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui Province 230031, People's Republic of China.,Department of Radiation Oncology, Anhui Provincial Cancer Hospital, Hefei, Anhui Province 230031, People's Republic of China
| | - Liping Yang
- Department of Radiation Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui Province 230031, People's Republic of China.,Department of Radiation Oncology, Anhui Provincial Cancer Hospital, Hefei, Anhui Province 230031, People's Republic of China
| | - Zhenchao Tao
- Department of Radiation Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui Province 230031, People's Republic of China.,Department of Radiation Oncology, Anhui Provincial Cancer Hospital, Hefei, Anhui Province 230031, People's Republic of China
| | - Jing Yang
- Department of Radiation Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui Province 230031, People's Republic of China.,Department of Radiation Oncology, Anhui Provincial Cancer Hospital, Hefei, Anhui Province 230031, People's Republic of China
| | - Yan Zhou
- Department of Radiation Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui Province 230031, People's Republic of China.,Department of Radiation Oncology, Anhui Provincial Cancer Hospital, Hefei, Anhui Province 230031, People's Republic of China
| | - Ru Wang
- Department of Radiation Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui Province 230031, People's Republic of China.,Department of Radiation Oncology, Anhui Provincial Cancer Hospital, Hefei, Anhui Province 230031, People's Republic of China
| | - Yangyang Zhang
- Department of Radiation Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui Province 230031, People's Republic of China.,Department of Radiation Oncology, Anhui Provincial Cancer Hospital, Hefei, Anhui Province 230031, People's Republic of China
| | - Yifan Huang
- Department of Radiation Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui Province 230031, People's Republic of China.,Department of Radiation Oncology, Anhui Provincial Cancer Hospital, Hefei, Anhui Province 230031, People's Republic of China
| | - Lingran Zhou
- Department of Radiation Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui Province 230031, People's Republic of China.,Department of Radiation Oncology, Anhui Provincial Cancer Hospital, Hefei, Anhui Province 230031, People's Republic of China
| | - Bin Sun
- Department of Radiation Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui Province 230031, People's Republic of China.,Department of Radiation Oncology, Anhui Provincial Cancer Hospital, Hefei, Anhui Province 230031, People's Republic of China
| | - Jin Gao
- Department of Radiation Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui Province 230031, People's Republic of China.,Department of Radiation Oncology, Anhui Provincial Cancer Hospital, Hefei, Anhui Province 230031, People's Republic of China
| |
Collapse
|